tiprankstipranks
Hofseth BioCare Advances Eosinophil Drug Candidate
Company Announcements

Hofseth BioCare Advances Eosinophil Drug Candidate

Hofseth Biocare ASA (HOFBF) has released an update.

Don't Miss Our Christmas Offers:

Hofseth BioCare ASA has announced the transfer of its drug candidate MA-022a, aimed at treating eosinophil-related conditions like asthma and eosinophilic esophagitis, to its subsidiary HBC Immunology Inc. This move, valuing the underlying patent at $4.5 million, will see HBC receiving shares in HBCI and is expected to result in a financial gain for HBC in the second quarter of 2024. The drug candidate demonstrates promise with a different treatment profile that could improve patient outcomes in these conditions.

For further insights into HOFBF stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks European Auto-Generated NewsdeskHofseth BioCare ASA Expands Production with New Plant
TipRanks Auto-Generated NewsdeskHofseth Biocare ASA Shows Strong Revenue Growth
TipRanks European Auto-Generated NewsdeskHofseth Biocare’s Breakthrough in Prostate Cancer
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App